New in epilepsy: promising therapeutic strategies

New treatment strategies are gaining attention in epilepsy, where current therapeutic options are ineffective for many. Learn more about the…

Read More

Epstein-Barr virus may be the predominant trigger of multiple sclerosis

A record-breaking study into the relationship between Epstein-Barr virus (EBV) infection and multiple sclerosis (MS) onset has revealed a 32-fold…

Read More

The present and future of biomarkers in MS

Biomarker research was a major talking point at ECTRIMS 2021. Discover the latest developments discussed at the meeting, from moving…

Read More

COVID-19 vaccination in patients with multiple sclerosis

Real-world data sets were presented at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS),…

Read More

Key themes in Parkinson’s disease research in 2021

Learn more about the major research themes in Parkinson’s disease, discussed at the International Congress of Parkinson’s Disease and Movement…

Read More

Daridorexant under FDA & EMA review for insomnia after Phase III success

Insomnia is a common sleep disorder with a prevalence ranging from 5.8–20.0%1 and associated with various comorbidities and major societal…

Read More

Highlights from the International Headache Congress 2021

VJNeurology are excited to bring you the latest updates from the International Headache Congress 2021. Learn more about the highlights…

Read More

Major pivotal study leads to FDA approval of the Vivistim Paired VNS System for treatment of upper limb impairments after chronic ischemic stroke

The results of the VNS-REHAB clinical trial demonstrated significant improvements in upper arm function after the application of vagus nerve…

Read More
The content of VJNeurology is intended for healthcare professionals